Early Intervention Makes All the Difference
Children who would otherwise fall far behind in language and social development, perhaps never to close the gap, can now grow alongside their peers.
The reason? Hearing loss can now be identified at birth, and that simple fact makes a world of difference.
Hearing loss is one of the most common problems found in newborns, affecting 12,000 children born in the U.S. each year.*
Auditory Neuropathy, a disorder characterized by dysfunction in the auditory pathway beyond the outer hair cells of the cochlea, affects up to 15% of infants with hearing impairment.*
The American Academy of Pediatrics (AAP) issued guidelines recommending that hospitals screen all babies for hearing loss before they leave the hospital.
A child's brain develops in response to the amount of sensory stimulation it receives. Children with unidentified hearing loss will not receive adequate sensory stimulation beginning at birth, and their language circuitry may never fully develop.
But children identified at birth as deaf or hard of hearing, who begin immediate therapy, can learn and progress at a rate comparable to children with normal hearing, regardless of the severity of their hearing loss. Their clinical outcome is phenomenal. In comparison, children identified just six months later may never catch up, even with extensive therapy. The consequent educational costs over a lifetime for these children are far higher than for children who are identified at birth.
With early intervention showing such clear advantages, universal newborn hearing screening has become the standard of care in hospitals throughout the country. Many states have passed legislation to ensure that babies are screened for hearing loss prior to leaving the newborn nursery.
Natus ALGO® Newborn Hearing Screeners meet the fundamental requirements for successful universal newborn hearing screening. A majority of hospitals in the United States that screen infants for hearing loss use the ALGO screener, and more than ten million babies have been screened with the ALGO device worldwide.*
*References available on file at Natus